When and How to Treat Relapsed Multiple Myeloma
Author(s) -
Nitya Nathwani,
Luca Bertamini,
Rahul Banerjee,
Francesca Gay,
Nina Shah,
Amrita Krishnan
Publication year - 2021
Publication title -
american society of clinical oncology educational book
Language(s) - English
Resource type - Journals
eISSN - 1548-8756
pISSN - 1548-8748
DOI - 10.1200/edbk_320129
Subject(s) - multiple myeloma , regimen , medicine , disease , intensive care medicine , preference , immunology , economics , microeconomics
The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease and prolonging survival. The wealth of novel regimens comes with the challenges of balancing toxicities and aligning a regimen with the biology of the myeloma and the nature of the relapse in conjunction with patient treatment history and personal preference. Herein, we provide an overview of treatment options for both early and late relapsing disease as well as a discussion of the role of emerging immune-based therapies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom